Cargando…
Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing
The Clinical and Laboratory Standards Institute recommends the use of Mueller Hinton (MH) medium to perform drug susceptibility testing (DST) of Mycobacterium avium complex (MAC) using the microdilution method. For MAC, there has been no study on the impact of media on the determination of minimum i...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042387/ https://www.ncbi.nlm.nih.gov/pubmed/32140138 http://dx.doi.org/10.3389/fmicb.2020.00081 |
_version_ | 1783501300228423680 |
---|---|
author | Jaffré, Jérémy Aubry, Alexandra Maitre , Thomas Morel, Florence Brossier, Florence Robert, Jérôme Sougakoff, Wladimir Veziris, Nicolas |
author_facet | Jaffré, Jérémy Aubry, Alexandra Maitre , Thomas Morel, Florence Brossier, Florence Robert, Jérôme Sougakoff, Wladimir Veziris, Nicolas |
author_sort | Jaffré, Jérémy |
collection | PubMed |
description | The Clinical and Laboratory Standards Institute recommends the use of Mueller Hinton (MH) medium to perform drug susceptibility testing (DST) of Mycobacterium avium complex (MAC) using the microdilution method. For MAC, there has been no study on the impact of media on the determination of minimum inhibitory concentrations (MICs) of antibiotics other than clarithromycin. This study aimed at determining the impact of two media used for DST of MAC and at augmenting the number of pertinent MICs for MAC species encountered in clinical practice. MICs of antibiotics used for the treatment of MAC infections were determined for 158 clinical MAC isolates (80 M. avium, 40 M. intracellulare, 35 M. chimaera, two M. yongonense and one M. timonense) in MH and 7H9 broths using the SLOMYCO Sensititre(TM) system (TREK Diagnostic Systems, East Grinstead, United Kingdom). The modal MICs determined in both media were the same for linezolid, moxifloxacin, rifabutin and amikacin but not for clarithromycin, rifampin and ethambutol. The kappa test for MICs converted to susceptibility categories showed an excellent agreement for clarithromycin, a moderate agreement for linezolid and a weak agreement for moxifloxacin and amikacin. For amikacin, 7H9 allowed a better distinction (fewer intermediate strains) of wild-type populations than MH. Existing breakpoints for linezolid and moxifloxacin are spread through the distribution of MICs for wild-type populations. The only breakpoints that can be used rationally are those for amikacin and clarithromycin. For amikacin, 7H9 performs better than MH, whereas both media perform equally for clarithromycin. Given that testing in 7H9, as opposed to MH, allows easier MIC measurements and yields greater reproducibility, we propose the use of 7H9 medium for DST of MAC. |
format | Online Article Text |
id | pubmed-7042387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70423872020-03-05 Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing Jaffré, Jérémy Aubry, Alexandra Maitre , Thomas Morel, Florence Brossier, Florence Robert, Jérôme Sougakoff, Wladimir Veziris, Nicolas Front Microbiol Microbiology The Clinical and Laboratory Standards Institute recommends the use of Mueller Hinton (MH) medium to perform drug susceptibility testing (DST) of Mycobacterium avium complex (MAC) using the microdilution method. For MAC, there has been no study on the impact of media on the determination of minimum inhibitory concentrations (MICs) of antibiotics other than clarithromycin. This study aimed at determining the impact of two media used for DST of MAC and at augmenting the number of pertinent MICs for MAC species encountered in clinical practice. MICs of antibiotics used for the treatment of MAC infections were determined for 158 clinical MAC isolates (80 M. avium, 40 M. intracellulare, 35 M. chimaera, two M. yongonense and one M. timonense) in MH and 7H9 broths using the SLOMYCO Sensititre(TM) system (TREK Diagnostic Systems, East Grinstead, United Kingdom). The modal MICs determined in both media were the same for linezolid, moxifloxacin, rifabutin and amikacin but not for clarithromycin, rifampin and ethambutol. The kappa test for MICs converted to susceptibility categories showed an excellent agreement for clarithromycin, a moderate agreement for linezolid and a weak agreement for moxifloxacin and amikacin. For amikacin, 7H9 allowed a better distinction (fewer intermediate strains) of wild-type populations than MH. Existing breakpoints for linezolid and moxifloxacin are spread through the distribution of MICs for wild-type populations. The only breakpoints that can be used rationally are those for amikacin and clarithromycin. For amikacin, 7H9 performs better than MH, whereas both media perform equally for clarithromycin. Given that testing in 7H9, as opposed to MH, allows easier MIC measurements and yields greater reproducibility, we propose the use of 7H9 medium for DST of MAC. Frontiers Media S.A. 2020-02-19 /pmc/articles/PMC7042387/ /pubmed/32140138 http://dx.doi.org/10.3389/fmicb.2020.00081 Text en Copyright © 2020 Jaffré, Aubry, Maitre, Morel, Brossier, Robert, Sougakoff, Veziris and the CNR-MyRMA (Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux). http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Jaffré, Jérémy Aubry, Alexandra Maitre , Thomas Morel, Florence Brossier, Florence Robert, Jérôme Sougakoff, Wladimir Veziris, Nicolas Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing |
title | Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing |
title_full | Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing |
title_fullStr | Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing |
title_full_unstemmed | Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing |
title_short | Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing |
title_sort | rational choice of antibiotics and media for mycobacterium avium complex drug susceptibility testing |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042387/ https://www.ncbi.nlm.nih.gov/pubmed/32140138 http://dx.doi.org/10.3389/fmicb.2020.00081 |
work_keys_str_mv | AT jaffrejeremy rationalchoiceofantibioticsandmediaformycobacteriumaviumcomplexdrugsusceptibilitytesting AT aubryalexandra rationalchoiceofantibioticsandmediaformycobacteriumaviumcomplexdrugsusceptibilitytesting AT maitrethomas rationalchoiceofantibioticsandmediaformycobacteriumaviumcomplexdrugsusceptibilitytesting AT morelflorence rationalchoiceofantibioticsandmediaformycobacteriumaviumcomplexdrugsusceptibilitytesting AT brossierflorence rationalchoiceofantibioticsandmediaformycobacteriumaviumcomplexdrugsusceptibilitytesting AT robertjerome rationalchoiceofantibioticsandmediaformycobacteriumaviumcomplexdrugsusceptibilitytesting AT sougakoffwladimir rationalchoiceofantibioticsandmediaformycobacteriumaviumcomplexdrugsusceptibilitytesting AT vezirisnicolas rationalchoiceofantibioticsandmediaformycobacteriumaviumcomplexdrugsusceptibilitytesting AT rationalchoiceofantibioticsandmediaformycobacteriumaviumcomplexdrugsusceptibilitytesting |